Anlon Healthcare approves issue of bonus shares in ratio of 1:1

Anlon Healthcare approves issue of bonus shares in ratio of 1:1

Anlon Healthcare Limited’s board convened on March 6, 2026, to deliberate on corporate actions, including the approval of a bonus share issuance in a 1:1 ratio. This decision aims to enhance shareholder value by increasing the number of shares held by existing investors without additional cost, potentially boosting liquidity and market accessibility. The company also considered a stock split and an increase in authorized share capital, though specific ratios or effective dates remain pending finalization.

The bonus issue aligns with the company’s strategy to improve investor sentiment following its August 2025 IPO, which raised ₹121.03 crore. Anlon Healthcare reported FY25 revenues of ₹120 crore, reflecting recovery after a regulatory shutdown in FY24. However, the company has not historically declared dividends and faces challenges, including strained working capital and pending GST disputes totaling ₹1.15 crore.

The board also closed the trading window for designated insiders during the meeting. While the bonus share issuance may dilute per-share value, it could signal confidence in future growth, particularly as the company expands in the pharmaceutical intermediates and APIs sector. Key peers like AMI Organics and Supriya Lifesciences reported higher FY25 revenues, highlighting competitive pressures.

Investors should monitor regulatory approvals and management commentary on how these actions align with long-term strategies. The company’s market capitalization currently stands at ₹616 crore, with a share price of ₹116.38 as of March 6. Further updates on the stock split or capital restructuring will be critical for assessing the impact on liquidity and shareholder equity.

(Source 1, 3, or 5): Source 1, 3, or 5
(Source 3): Source 3
(Source 4): Source 4